NCT01058369 - Exjade-Early-Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Deferasirox (Novartis Pharma)

Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol

Trial Locations (1)

Medizinische Klinik 5, Universitätsklinikum Erlangen, Erlangen